A new report assesses the viability of new healthcare expansion options with Medicaid insurers.
Mona Shah
If Medicaid managed care plans offer coverage to more people and in more places, it could help protect consumers from higher healthcare costs, according to a new report.
The number of insurers participating in ACA individual insurance marketplaces has decreased over time, reveals a new report from the Urban Institute, with support from the Robert Wood Johnson Foundation (RWJF). Fewer insurers often leads to higher premiums for enrollees.
Related: The Future of the ACA
“This study looks at the possibility of convincing more Medicaid insurers to participate in the marketplaces and the impact that would have on lowering marketplace premiums,” says Mona Shah, senior program officer at RWJF. “Some Medicaid insurers have found that participation in the marketplace have expanded their footprints to new states and markets.”
Key findings include:
Generally, interviewees were in favor of Medicaid buy-in proposals, according to Shah. “These plans could allow Medicaid beneficiaries to retain continuous coverage year-round who may otherwise come on and off insurer’s Medicaid plans, as individuals’ incomes rise and fall,” she says.
Related: Top Medicaid Trends in 2019
The findings suggest that the closer Medicaid buy-in proposals hew to Medicaid program rules, the more likely that Medicaid insurers would participate in such programs, according to Shah.
There are three top reasons Medicaid insurers do not sell plans in ACA marketplaces, according to Shah:
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More
Two Opdivo Updates from Bristol Myers Squibb
May 14th 2024First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
Read More